SCHEMBL18609243

SCHEMBL18609243

COc1ccc(C2CNC(=O)[C@H]2NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 16/20 0.60
FPR2 P25090 15/20 0.60
KDM1A O60341 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18578795 1.00 FPR1 (0.60) FPR1FPR2KDM1A
SCHEMBL18106404 1.00 FPR1 (0.60) FPR1FPR2KDM1A
SCHEMBL18609449 1.00 FPR1 (0.60) FPR1FPR2KDM1A
SCHEMBL29434176 1.00 FPR1 (0.60) FPR1FPR2KDM1A
SCHEMBL18106402 1.00 FPR1 (0.60) FPR1FPR2KDM1A
SCHEMBL18117785 1.00 FPR1 (0.60) FPR1FPR2KDM1A
SCHEMBL18106592 0.84 FPR2 (0.66) FPR1FPR2
SCHEMBL18264316 0.84 FPR2 (0.66) FPR1FPR2
SCHEMBL21341976 0.82 KDM1A (0.53) FPR1FPR2KDM1A
SCHEMBL21341982 0.82 KDM1A (0.53) FPR1FPR2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2019-11-05 US disclosed
US-10252992-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2019-04-09 US disclosed
US-10029983-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2018-07-24 US disclosed
US-20180044290-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KYORIN SEIYAKU KK (JP) 2018-02-15 US disclosed
US-9822069-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2017-11-21 US disclosed
US-20170066718-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KYORIN PHARMACEUTICAL CO., LTD. (JP) 2017-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 FPR1 1/4885FPR2 2/4885KDM1A 4486/4885
US-10029983-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 FPR1 1/4885FPR2 2/4885KDM1A 4486/4885
US-20170066718-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF FPR1, FPR2, FPR3 FPR1 1/4885FPR2 2/4885KDM1A 4486/4885
US-20180044290-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF FPR1, FPR2, FPR3 FPR1 1/4885FPR2 2/4885KDM1A 4486/4885
US-10252992-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 FPR1 1/4885FPR2 2/4885KDM1A 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.